SCHEMBL4944253

SCHEMBL4944253

COC(=O)c1ccc(-c2cc(F)ccc2C)o1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC9A1 P19634 5/20 0.64
S1PR4 O95977 2/20 0.53
S1PR2 O95136 1/20 0.53
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
ALDH1A1 P00352 3/20 0.52
HPGD P15428 2/20 0.52
LMNA P02545 3/20 0.50
MAPT P10636 2/20 0.50
POLB P06746 2/20 0.50
MAPK1 P28482 1/20 0.50
RECQL P46063 1/20 0.50
HTT P42858 2/20 0.47
KDM4E B2RXH2 1/20 0.47
GAA P10253 1/20 0.47
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
SETD7 Q8WTS6 1/20 0.43
PDE4B Q07343 1/20 0.43
PDE4D Q08499 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4943691 0.87 S1PR2 (0.61) SLC9A1S1PR4S1PR2MEN1KMT2A
SCHEMBL4946556 0.85 MEN1 (0.72) SLC9A1S1PR4MEN1KMT2AALDH1A1
SCHEMBL4943636 0.84 SLC9A1 (0.67) SLC9A1S1PR4S1PR2ALDH1A1HPGD
SCHEMBL4945613 0.84 SLC9A1 (0.60) SLC9A1S1PR4S1PR2KMT2AALDH1A1
SCHEMBL1330592 0.79 SLC9A1 (0.62) SLC9A1S1PR4S1PR2MEN1KMT2A
SCHEMBL4946365 0.78 ALDH1A1 (0.61) SLC9A1S1PR4MEN1KMT2AALDH1A1
SCHEMBL1330595 0.78 SLC9A1 (1.00) SLC9A1
SCHEMBL21981938 0.77 HTT (0.67) MEN1KMT2AALDH1A1HPGDLMNA
SCHEMBL4942913 0.77 SLC9A1 (0.64) SLC9A1S1PR4S1PR2MEN1KMT2A
SCHEMBL22067542 0.77 KDM4E (0.50) ALDH1A1MAPTPOLBRECQLHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7351843-B2 Furancarbonylguanidine derivatives, their preparation and pharmaceutical compositions containing them KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2008-04-01 US disclosed
US-20070299131-A1 Furancarbonylguanidine Derivatives, Their Preparation and Pharmaceutical Compositions Containing Them KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2007-12-27 US disclosed
EP-1697335-A1 FURANCARBONYLGUANIDINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2006-09-06 EP disclosed
WO-2005063727-A1 FURANCARBONYLGUANIDINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2005-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299131-A1 Furancarbonylguanidine Derivatives, Their Preparation and Pharmaceutical Compositions Containing Them SLC9A1, NHERF1, SLC5A1 SLC9A1 1/4885S1PR4 2223/4885S1PR2 1396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.